Publications:

---

A recurrent inflammatory myofibroblastic tumor patient with two novel ALK fusions: a case report.

Translational Cancer Research

Xu, Xiumei X; Li, Ling L; Zhang, Yaxuan Y; Meng, Fanfan F; Xie, Hongmei H; Duan, Ruiqi R

Publication Date: 2022-09

Variant appearance in text: ALK: L1196Q

PubMed Link: 36237256

Variant Present in the following documents:

• Main text
• tcr-11-09-3379.pdf

View BVdb publication page

---

ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.

Jco Precision Oncology

Ambrosini, Margherita M; Del Re, Marzia M; Manca, Paolo P; Hendifar, Andrew A; Drilon, Alexander A; Harada, Guilherme G; Ree, Anne Hansen AH; Klempner, Samuel S; Mælandsmo, Gunhild Mari GM; Flatmark, Kjersti K; Russnes, Hege G HG; Cleary, James M JM; Singh, Harshabad H; Sottotetti, Elisa E; Martinetti, Antonia A; Randon, Giovanni G; Sartore-Bianchi, Andrea A; Capone, Iolanda I; Milione, Massimo M; Di Bartolomeo, Maria M; Pietrantonio, Filippo F

Publication Date: 2022-04

Variant appearance in text: ALK: L1196Q

PubMed Link: 35476549

Variant Present in the following documents:

• Main text
• po-6-e2200015.pdf

View BVdb publication page

---

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report.

Diagnostics (Basel, Switzerland)

Catino, Annamaria A; Lacalamita, Rosanna R; De Summa, Simona S; Pesola, Francesco F; Tommasi, Stefania S; Galetta, Domenico D

Publication Date: 2022-03-11

Variant appearance in text: ALK: L1196Q

PubMed Link: 35328235

Variant Present in the following documents:

• diagnostics-12-00682.pdf

View BVdb publication page

---

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Cancer Science

Koga, Takamasa T; Suda, Kenichi K; Mitsudomi, Tetsuya T

Publication Date: 2022-03

Variant appearance in text: ALK: L1196Q

PubMed Link: 34997674

Variant Present in the following documents:

• CAS-113-815.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: L1196Q

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: L1196Q

PubMed Link: 34885113

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.

Npj Precision Oncology

Angeles, Arlou Kristina AK; Christopoulos, Petros P; Yuan, Zhao Z; Bauer, Simone S; Janke, Florian F; Ogrodnik, Simon John SJ; Reck, Martin M; Schlesner, Matthias M; Meister, Michael M; Schneider, Marc A MA; Dietz, Steffen S; Stenzinger, Albrecht A; Thomas, Michael M; Sültmann, Holger H

Publication Date: 2021-12-07

Variant appearance in text: ALK: 3587T>A; Leu1196Gln

PubMed Link: 34876698

Variant Present in the following documents:

• 41698_2021_239_MOESM1_ESM.pdf

View BVdb publication page

---

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.

Cancers

Villa, Matteo M; Sharma, Geeta G GG; Manfroni, Chiara C; Cortinovis, Diego D; Mologni, Luca L

Publication Date: 2021-10-14

Variant appearance in text: ALK: L1196Q

PubMed Link: 34680298

Variant Present in the following documents:

• Main text
• cancers-13-05149.pdf

View BVdb publication page

---

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology

Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C

Publication Date: 2021

Variant appearance in text: ALK: L1196Q

PubMed Link: 34630336

Variant Present in the following documents:

• Table_1.xlsx, sheet 2

View BVdb publication page

---

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping.

Jto Clinical And Research Reports

Lawrence, Marissa N MN; Tamen, Rubii M RM; Martinez, Pablo P; Sable-Hunt, Alicia A; Addario, Tony T; Barbour, Pete P; Shaffer, Tristan T; Hosseini, Seyed Ali SA; Bertucci, Caterina C; Lim, Lee P LP; Hong, Fangxin F; Michael, Kesi K; Simon, George R GR; Riess, Jonathan W JW; Awad, Mark M MM; Oxnard, Geoffrey R GR

Publication Date: 2021-04

Variant appearance in text: ALK: L1196Q

PubMed Link: 34590008

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement.

Jto Clinical And Research Reports

Longo, Vito V; Catino, Annamaria A; Montrone, Michele M; Pizzutilo, Pamela P; Ugenti, Ippazio I; Lacalamita, Rosanna R; Del Bene, Gabriella G; Pesola, Francesco F; Marech, Ilaria I; Galetta, Domenico D

Publication Date: 2020-06

Variant appearance in text: ALK: L1196Q

PubMed Link: 34589934

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools.

Scientific Reports

Garcia, Jessica J; Kamps-Hughes, Nick N; Geiguer, Florence F; Couraud, Sébastien S; Sarver, Brice B; Payen, Léa L; Ionescu-Zanetti, Cristian C

Publication Date: 2021-05-24

Variant appearance in text: ALK: L1196Q

PubMed Link: 34031447

Variant Present in the following documents:

• 41598_2021_89592_MOESM1_ESM.xlsx, sheet 4

View BVdb publication page

---

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Nature Communications

Mizuta, Hayato H; Okada, Koutaroh K; Araki, Mitsugu M; Adachi, Jun J; Takemoto, Ai A; Kutkowska, Justyna J; Maruyama, Kohei K; Yanagitani, Noriko N; Oh-Hara, Tomoko T; Watanabe, Kana K; Tamai, Keiichi K; Friboulet, Luc L; Katayama, Kazuhiro K; Ma, Biao B; Sasakura, Yoko Y; Sagae, Yukari Y; Kukimoto-Niino, Mutsuko M; Shirouzu, Mikako M; Takagi, Satoshi S; Simizu, Siro S; Nishio, Makoto M; Okuno, Yasushi Y; Fujita, Naoya N; Katayama, Ryohei R

Publication Date: 2021-02-24

Variant appearance in text: ALK: L1196Q

PubMed Link: 33627640

Variant Present in the following documents:

• Main text
• 41467_2021_21396_MOESM1_ESM.pdf
• 41467_2021_Article_21396.pdf

View BVdb publication page

---

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.

Esmo Open

Danesi, R R; Fogli, S S; Indraccolo, S S; Del Re, M M; Dei Tos, A P AP; Leoncini, L L; Antonuzzo, L L; Bonanno, L L; Guarneri, V V; Pierini, A A; Amunni, G G; Conte, P P

Publication Date: 2021-04

Variant appearance in text: ALK: L1196Q

PubMed Link: 33540286

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Novel ALK mutation with durable response to brigatinib-a case report.

Translational Lung Cancer Research

Latif, Hira H; Liu, Stephen V SV

Publication Date: 2020-10

Variant appearance in text: ALK: L1196Q

PubMed Link: 33209633

Variant Present in the following documents:

• Main text
• tlcr-09-05-2145.pdf

View BVdb publication page

---

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing.

Oncotargets And Therapy

Zhang, Chenlu C; Wang, Zhiming Z; Zhuang, Rongyuan R; Guo, Xi X; Feng, Yi Y; Shen, Feng F; Liu, Wenshuai W; Zhang, Yong Y; Tong, Hanxing H; Sun, Wending W; Liu, Jun J; Wang, Guan G; Dai, Chun C; Lu, Weiqi W; Zhou, Yuhong Y

Publication Date: 2020

Variant appearance in text: ALK: L1196Q

PubMed Link: 33116613

Variant Present in the following documents:

• Main text
• ott-13-10335.pdf

View BVdb publication page

---

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.

Plos One

Remon, Jordi J; Swalduz, Aurelie A; Planchard, David D; Ortiz-Cuaran, Sandra S; Mezquita, Laura L; Lacroix, Ludovic L; Jovelet, Cecile C; Rouleau, Etienne E; Leonce, Camille C; De Kievit, Frank F; Morris, Clive C; Jones, Greg G; Mercier, Kelly K; Howarth, Karen K; Green, Emma E; Pérol, Maurice M; Saintigny, Pierre P; Besse, Benjamin B

Publication Date: 2020

Variant appearance in text: ALK: L1196Q

PubMed Link: 32525942

Variant Present in the following documents:

• pone.0234302.s001.xlsx, sheet 1

View BVdb publication page

---

Landscape of drug-resistance mutations in kinase regulatory hotspots.

Briefings In Bioinformatics

Kim, Pora P; Li, Hanyang H; Wang, Junmei J; Zhao, Zhongming Z

Publication Date: 2021-05-20

Variant appearance in text: ALK: L1196Q

PubMed Link: 32510566

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.

Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association

Hescheler, Daniel A DA; Plum, Patrick S PS; Zander, Thomas T; Quaas, Alexander A; Korenkov, Michael M; Gassa, Asmae A; Michel, Maximilian M; Bruns, Christiane J CJ; Alakus, Hakan H

Publication Date: 2020-07

Variant appearance in text: ALK: L1196Q

PubMed Link: 32107691

Variant Present in the following documents:

• 10120_2020_1045_MOESM1_ESM.xlsx, sheet 12

View BVdb publication page

---

Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method.

Scientific Reports

Ono, Fumie F; Chiba, Shuntaro S; Isaka, Yuta Y; Matsumoto, Shigeyuki S; Ma, Biao B; Katayama, Ryohei R; Araki, Mitsugu M; Okuno, Yasushi Y

Publication Date: 2020-02-07

Variant appearance in text: ALK: L1196Q

PubMed Link: 32034220

Variant Present in the following documents:

• Main text
• 41598_2020_Article_58877.pdf

View BVdb publication page

---

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Dagogo-Jack, Ibiayi I; Rooney, Marguerite M; Lin, Jessica J JJ; Nagy, Rebecca J RJ; Yeap, Beow Y BY; Hubbeling, Harper H; Chin, Emily E; Ackil, Jennifer J; Farago, Anna F AF; Hata, Aaron N AN; Lennerz, Jochen K JK; Gainor, Justin F JF; Lanman, Richard B RB; Shaw, Alice T AT

Publication Date: 2019-11-15

Variant appearance in text: ALK: L1196Q

PubMed Link: 31358542

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.

Journal Of Medical Genetics

Peng, Muyun M; Xie, Yuancai Y; Li, Xiaohua X; Qian, Youhui Y; Tu, Xiaonian X; Yao, Xumei X; Cheng, Fangsheng F; Xu, Feiyue F; Kong, Deju D; He, Bing B; Liu, Chaoyu C; Cao, Fengjun F; Yang, Haoxian H; Yu, Fenglei F; Xu, Chuanbo C; Tian, Geng G

Publication Date: 2019-10

Variant appearance in text: ALK: 3587T>A; Leu1196Gln

PubMed Link: 30981987

Variant Present in the following documents:

• jmedgenet-2018-105825supp002.xlsx, sheet 4

View BVdb publication page

---

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Ebiomedicine

Okada, Koutaroh K; Araki, Mitsugu M; Sakashita, Takuya T; Ma, Biao B; Kanada, Ryo R; Yanagitani, Noriko N; Horiike, Atsushi A; Koike, Sumie S; Oh-Hara, Tomoko T; Watanabe, Kana K; Tamai, Keiichi K; Maemondo, Makoto M; Nishio, Makoto M; Ishikawa, Takeshi T; Okuno, Yasushi Y; Fujita, Naoya N; Katayama, Ryohei R

Publication Date: 2019-03

Variant appearance in text: ALK: L1196Q

PubMed Link: 30662002

Variant Present in the following documents:

• Main text
• main.pdf
• mmc1.pdf

View BVdb publication page

---

Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.

Genome Medicine

Heim, Daniel D; Montavon, Grégoire G; Hufnagl, Peter P; Müller, Klaus-Robert KR; Klauschen, Frederick F

Publication Date: 2018-11-15

Variant appearance in text: ALK: L1196Q

PubMed Link: 30442178

Variant Present in the following documents:

• 13073_2018_591_MOESM4_ESM.xlsx, sheet 1

View BVdb publication page

---

A Computational Approach for Prioritizing Selection of Therapies Targeting Drug Resistant Variation in Anaplastic Lymphoma Kinase.

Amia Joint Summits On Translational Science Proceedings. Amia Joint Summits On Translational Science

McCoy, Matthew D MD; Madhavan, Subha S

Publication Date: 2018

Variant appearance in text: ALK: L1196Q

PubMed Link: 29888064

Variant Present in the following documents:

• Main text
• 2839937.pdf

View BVdb publication page

---

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

McCoach, Caroline E CE; Blakely, Collin M CM; Banks, Kimberly C KC; Levy, Benjamin B; Chue, Ben M BM; Raymond, Victoria M VM; Le, Anh T AT; Lee, Christine E CE; Diaz, Joseph J; Waqar, Saiama N SN; Purcell, William T WT; Aisner, Dara L DL; Davies, Kurtis D KD; Lanman, Richard B RB; Shaw, Alice T AT; Doebele, Robert C RC

Publication Date: 2018-06-15

Variant appearance in text: ALK: L1196Q

PubMed Link: 29599410

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Cancers

Sharma, Geeta Geeta GG; Mota, Ines I; Mologni, Luca L; Patrucco, Enrico E; Gambacorti-Passerini, Carlo C; Chiarle, Roberto R

Publication Date: 2018-02-28

Variant appearance in text: ALK: L1196Q

PubMed Link: 29495603

Variant Present in the following documents:

• Main text
• cancers-10-00062.pdf

View BVdb publication page

---

Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.

Genome Research

Brammeld, Jonathan S JS; Petljak, Mia M; Martincorena, Inigo I; Williams, Steven P SP; Alonso, Luz Garcia LG; Dalmases, Alba A; Bellosillo, Beatriz B; Robles-Espinoza, Carla Daniela CD; Price, Stacey S; Barthorpe, Syd S; Tarpey, Patrick P; Alifrangis, Constantine C; Bignell, Graham G; Vidal, Joana J; Young, Jamie J; Stebbings, Lucy L; Beal, Kathryn K; Stratton, Michael R MR; Saez-Rodriguez, Julio J; Garnett, Mathew M; Montagut, Clara C; Iorio, Francesco F; McDermott, Ultan U

Publication Date: 2017-04

Variant appearance in text: ALK: 3587T>A; L1196Q

PubMed Link: 28179366

Variant Present in the following documents:

• supp_gr.213546.116_Supplemental_Table_S7.xlsx, sheet 1

View BVdb publication page

---

Targeting ALK: Precision Medicine Takes on Drug Resistance.

Cancer Discovery

Lin, Jessica J JJ; Riely, Gregory J GJ; Shaw, Alice T AT

Publication Date: 2017-02

Variant appearance in text: ALK: L1196Q

PubMed Link: 28122866

Variant Present in the following documents:

• Main text

View BVdb publication page

---

ALK: a tyrosine kinase target for cancer therapy.

Cold Spring Harbor Molecular Case Studies

Holla, Vijaykumar R VR; Elamin, Yasir Y YY; Bailey, Ann Marie AM; Johnson, Amber M AM; Litzenburger, Beate C BC; Khotskaya, Yekaterina B YB; Sanchez, Nora S NS; Zeng, Jia J; Shufean, Md Abu MA; Shaw, Kenna R KR; Mendelsohn, John J; Mills, Gordon B GB; Meric-Bernstam, Funda F; Simon, George R GR

Publication Date: 2017-01

Variant appearance in text: ALK: L1196Q

PubMed Link: 28050598

Variant Present in the following documents:

• Main text
• HollaMCS001115.pdf

View BVdb publication page

---

Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.

World Journal Of Clinical Oncology

Mologni, Luca L

Publication Date: 2015-10-10

Variant appearance in text: ALK: L1196Q

PubMed Link: 26468446

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

The Journal Of Clinical Investigation

Hoareau-Aveilla, Coralie C; Valentin, Thibaud T; Daugrois, Camille C; Quelen, Cathy C; Mitou, Géraldine G; Quentin, Samuel S; Jia, Jinsong J; Spicuglia, Salvatore S; Ferrier, Pierre P; Ceccon, Monica M; Giuriato, Sylvie S; Gambacorti-Passerini, Carlo C; Brousset, Pierre P; Lamant, Laurence L; Meggetto, Fabienne F

Publication Date: 2015-09

Variant appearance in text: ALK: L1196Q

PubMed Link: 26258416

Variant Present in the following documents:

• Main text

View BVdb publication page

---

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.

Oncotarget

Mologni, Luca L; Ceccon, Monica M; Pirola, Alessandra A; Chiriano, Gianpaolo G; Piazza, Rocco R; Scapozza, Leonardo L; Gambacorti-Passerini, Carlo C

Publication Date: 2015-03-20

Variant appearance in text: ALK: L1196Q

PubMed Link: 25749034

Variant Present in the following documents:

• Main text
• oncotarget-06-5720.pdf
• oncotarget-06-5720-s001.pdf

View BVdb publication page

---

The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.

Oncotarget

George, Suraj Konnath SK; Vishwamitra, Deeksha D; Manshouri, Roxsan R; Shi, Ping P; Amin, Hesham M HM

Publication Date: 2014-07-30

Variant appearance in text: ALK: L1196Q

PubMed Link: 25026277

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.

Journal Of Cancer Research And Clinical Oncology

Zdzalik, Daria D; Dymek, Barbara B; Grygielewicz, Paulina P; Gunerka, Pawel P; Bujak, Anna A; Lamparska-Przybysz, Monika M; Wieczorek, Maciej M; Dzwonek, Karolina K

Publication Date: 2014-04

Variant appearance in text: ALK: L1196Q

PubMed Link: 24509625

Variant Present in the following documents:

• Main text
• 432_2014_Article_1589.pdf

View BVdb publication page

---